ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.8019
0.04%
Brent Oil
84.185
0.28%
Bitcoin
62,935.41
-0.18%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) Noticias

ALLO

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALLO
FechaHoraFuenteTítuloSímboloCompañía
06/05/202407:30GlobeNewswire Inc.Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
26/04/202407:30GlobeNewswire Inc.Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaNASDAQ:ALLOAllogene Therapeutics Inc
09/04/202407:30GlobeNewswire Inc.Allogene Therapeutics Announces Q2 Investor Conference ParticipationNASDAQ:ALLOAllogene Therapeutics Inc
14/03/202415:05GlobeNewswire Inc.Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
12/03/202407:30GlobeNewswire Inc.Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseNASDAQ:ALLOAllogene Therapeutics Inc
05/03/202407:30GlobeNewswire Inc.Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
28/02/202407:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202407:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202407:30GlobeNewswire Inc.Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaNASDAQ:ALLOAllogene Therapeutics Inc
31/01/202416:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
22/01/202415:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
16/01/202415:05GlobeNewswire Inc.Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202415:15GlobeNewswire Inc.Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202415:05GlobeNewswire Inc.Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
03/01/202415:05GlobeNewswire Inc.Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
09/12/202311:00GlobeNewswire Inc.Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
01/12/202307:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in December Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202311:00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202311:00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202315:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202315:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202315:02GlobeNewswire Inc.Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
30/10/202307:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in November Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
26/10/202307:30GlobeNewswire Inc.Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:ALLOAllogene Therapeutics Inc
17/10/202315:34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLOAllogene Therapeutics Inc
16/10/202307:30GlobeNewswire Inc.Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial OfficerNASDAQ:ALLOAllogene Therapeutics Inc
27/09/202308:09GlobeNewswire Inc.Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
05/09/202307:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in September Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
14/08/202318:28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLO

Su Consulta Reciente

FX
USDMXN
US Dollar vs MXN
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
AMEX
XLF
Financial Select Sector
NASDAQ
MSFT
Microsoft
NYSE
VZ
Verizon Communications
NYSE
NKE
Nike
NYSE
BAC
Bank of America
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
NYSE
MCD
McDonalds
FX
EURMXN
Euro vs MXN
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados